SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced its financial results for the year ended December 31, 2025, along with a corporate update. The company reported a net loss of $26.9 million, or $0.25 per share, compared to a net loss of $30.9 million, or $0.50 per share, for the previous year. Research and development expenses decreased to $16.0 million from $19.1 million in 2024, primarily due to reduced clinical trial expenses. General and administrative expenses remained relatively stable at $12.3 million. As of December 31, 2025, the company had $71.8 million in cash and cash equivalents, bolstered by an additional $42.6 million received from warrant exercises in early 2026. The company highlighted significant advancements in its clinical programs, particularly the Phase 3 REGAL trial of Galinpepimut-S (GPS) in acute myeloid leukemia (AML) and the initiation of a Phase 2 trial for SLS009 in newly diagnosed AML patients. The CEO, Angelos Stergiou, expressed optimism about the company's trajectory in 2026, citing the potential for GPS to become a leading immunotherapeutic option in AML. The company also announced a strategic collaboration with IMPACT-AML to expand its clinical program in Europe, aiming to enroll approximately 40 patients in a study combining SLS009 with azacitidine and venetoclax. Overall, SELLAS is positioned for a pivotal year ahead with a strong financial foundation and promising clinical developments.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.